Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 70

1.

LBA-008Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO).

Al-Batran SE, Pauligk C, Homann N, Schmalenberg H, Kopp HG, Haag GM, Luley Kim B, Schmiegel Wolff H, Folprecht G, Probst S, Prasnikar N, Thuss-Patience Peter C, Trojan J, Goetze TO, Meiler J, Schuler Martin H, Jäger E, Hofheinz RD.

Ann Oncol. 2017 Jun 1;28(suppl_3). doi: 10.1093/annonc/mdx302.007. No abstract available.

PMID:
30052790
2.

EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity.

Hofheinz RD, Lorenzen S, Trojan J, Ocvirk J, Ettrich TJ, Al-Batran SE, Schulz H, Homann N, Feustel HP, Schatz M, Kripp M, Schulte N, Tetyusheva M, Heeger S, Vlassak S, Merx K.

Ann Oncol. 2018 Apr 1;29(4):1010-1015. doi: 10.1093/annonc/mdy015.

PMID:
29360920
3.

The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI.

Al-Batran SE, Goetze TO, Mueller DW, Vogel A, Winkler M, Lorenzen S, Novotny A, Pauligk C, Homann N, Jungbluth T, Reissfelder C, Caca K, Retter S, Horndasch E, Gumpp J, Bolling C, Fuchs KH, Blau W, Padberg W, Pohl M, Wunsch A, Michl P, Mannes F, Schwarzbach M, Schmalenberg H, Hohaus M, Scholz C, Benckert C, Knorrenschild JR, Kanngießer V, Zander T, Alakus H, Hofheinz RD, Roedel C, Shah MA, Sasako M, Lorenz D, Izbicki J, Bechstein WO, Lang H, Moenig SP.

BMC Cancer. 2017 Dec 28;17(1):893. doi: 10.1186/s12885-017-3918-9.

4.

Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.

Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, Schmalenberg H, Luley KB, Prasnikar N, Egger M, Probst S, Messmann H, Moehler M, Fischbach W, Hartmann JT, Mayer F, Höffkes HG, Koenigsmann M, Arnold D, Kraus TW, Grimm K, Berkhoff S, Post S, Jäger E, Bechstein W, Ronellenfitsch U, Mönig S, Hofheinz RD.

JAMA Oncol. 2017 Sep 1;3(9):1237-1244. doi: 10.1001/jamaoncol.2017.0515.

5.

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.

Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Königsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A.

Lancet Oncol. 2016 Dec;17(12):1697-1708. doi: 10.1016/S1470-2045(16)30531-9. Epub 2016 Oct 22.

PMID:
27776843
6.

VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Thomaidis T, Maderer A, Al-Batran SE, Kany J, Pauligk C, Steinmetz K, Schad A, Hofheinz R, Schmalenberg H, Homann N, Galle PR, Moehler M.

BMC Cancer. 2014 Jul 1;14:476. doi: 10.1186/1471-2407-14-476.

7.

Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy.

Lorenzen S, Thuss-Patience P, Al-Batran SE, Lordick F, Haller B, Schuster T, Pauligk C, Luley K, Bichev D, Schumacher G, Homann N.

Ann Oncol. 2013 Aug;24(8):2068-73. doi: 10.1093/annonc/mdt141. Epub 2013 Apr 16.

PMID:
23592699
8.

Aneuploidy-associated gene expression signatures characterize malignant transformation in ulcerative colitis.

Gerling M, Nousiainen K, Hautaniemi S, Krüger S, Fritzsche B, Homann N, Bruch HP, Auer G, Roblick UJ, Ried T, Habermann JK.

Inflamm Bowel Dis. 2013 Mar-Apr;19(4):691-703. doi: 10.1097/MIB.0b013e31827eeaa4.

PMID:
23455720
9.

Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Kripp M, Al-Batran SE, Rosowski J, Pauligk C, Homann N, Hartmann JT, Moehler M, Hofheinz RD.

Gastric Cancer. 2014 Jan;17(1):181-7. doi: 10.1007/s10120-013-0242-1. Epub 2013 Feb 28.

PMID:
23455717
10.

Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer.

Lorenzen S, Pauligk C, Homann N, Schmalenberg H, Jäger E, Al-Batran SE.

Br J Cancer. 2013 Feb 19;108(3):519-26. doi: 10.1038/bjc.2012.588. Epub 2013 Jan 15.

11.

The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+).

Al-Batran SE, Pauligk C, Homann N, Hartmann JT, Moehler M, Probst S, Rethwisch V, Stoehlmacher-Williams J, Prasnikar N, Hollerbach S, Bokemeyer C, Mahlberg R, Hofheinz RD, Luley K, Kullmann F, Jäger E.

Eur J Cancer. 2013 Mar;49(4):835-42. doi: 10.1016/j.ejca.2012.09.025. Epub 2012 Oct 11.

PMID:
23063354
12.

The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer.

Al-Batran SE, Pauligk C, Wirtz R, Werner D, Steinmetz K, Homann N, Schmalenberg H, Hofheinz RD, Hartmann JT, Atmaca A, Altmannsberger HM, Jäger E.

Ann Oncol. 2012 Jul;23(7):1699-705. doi: 10.1093/annonc/mdr552. Epub 2011 Nov 23.

PMID:
22112973
13.

Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel.

Homann N, Pauligk C, Luley K, Werner Kraus T, Bruch HP, Atmaca A, Noack F, Altmannsberger HM, Jäger E, Al-Batran SE.

Int J Cancer. 2012 Apr 1;130(7):1706-13. doi: 10.1002/ijc.26180. Epub 2011 Aug 5.

14.

Local calprotectin production in colorectal cancer and polyps--active neutrophil recruitment in carcinogenesis.

Luley K, Noack F, Lehnert H, Homann N.

Int J Colorectal Dis. 2011 May;26(5):603-7. doi: 10.1007/s00384-011-1165-0. Epub 2011 Mar 5.

PMID:
21380506
15.

Ethanol-mediated carcinogenesis in the human esophagus implicates CYP2E1 induction and the generation of carcinogenic DNA-lesions.

Millonig G, Wang Y, Homann N, Bernhardt F, Qin H, Mueller S, Bartsch H, Seitz HK.

Int J Cancer. 2011 Feb 1;128(3):533-40. doi: 10.1002/ijc.25604.

16.

Preclinical and clinical aspects of carboplatin and gemcitabine combined with whole-body hyperthermia for pancreatic adenocarcinoma.

Bakshandeh-Bath A, Stoltz AS, Homann N, Wagner T, Stölting S, Peters SO.

Anticancer Res. 2009 Aug;29(8):3069-77.

17.

Manganese superoxide dismutase (MnSOD) polymorphism, alcohol, cigarette smoking and risk of oesophageal cancer.

Sun L, König IR, Homann N.

Alcohol Alcohol. 2009 Jul-Aug;44(4):353-7. doi: 10.1093/alcalc/agp025. Epub 2009 May 18.

PMID:
19451660
18.

Clinical trial: cyclophosphamide pulse therapy - a promising therapeutic alternative in refractory Crohn's disease.

Schmidt KJ, Fellermann K, Wellhöner P, Weitz G, Homann N, Herrlinger K, Lehnert H, Ludwig D, Büning J.

Aliment Pharmacol Ther. 2009 Jun 15;29(12):1230-9. doi: 10.1111/j.1365-2036.2009.03999.x. Epub 2009 Mar 19.

19.

p53 Mutations in carcinoma of the esophagus and gastroesophageal junction.

Sengpiel C, König IR, Rades D, Noack F, Duchrow M, Schild SE, Ludwig D, Homann N.

Cancer Invest. 2009 Jan;27(1):96-104. doi: 10.1080/07357900802161047.

PMID:
19160092
20.

Alcohol and colorectal cancer: the role of alcohol dehydrogenase 1C polymorphism.

Homann N, König IR, Marks M, Benesova M, Stickel F, Millonig G, Mueller S, Seitz HK.

Alcohol Clin Exp Res. 2009 Mar;33(3):551-6. doi: 10.1111/j.1530-0277.2008.00868.x. Epub 2008 Dec 19.

PMID:
19120062

Supplemental Content

Loading ...
Support Center